# US 2025/0152525 A1 · Compositions and methods for the treatment of testosterone deficiency in males

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152525 A1
- Document ID: US20250152525A1
- Status: Published application
- Kind: A1
- Application number: 18/505,241
- Filed: 2023-11-09
- Published: 2025-05-15
- Earliest claimed: 2023-11-09
- Assignees: Woody's Medical LLC
- Applicants: Woody's Medical LLC
- Inventors: Austin Lucht; Suzanne Bentz
- Web page: https://patentgrep.com/patent/US20250152525A1

## CPC

- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

In various embodiments compositions for the treatment of testosterone deficiency (TD, or “low-T”) and/or secondary hypogonadotropic hypogonadism comprise at least one selective estrogen receptor modulator (SERM) and a carrier, wherein the composition is entirely devoid of any estrogenically active substances capable of lowering testosterone levels. In preferred embodiments, compositions comprise only the (E)-stereoisomer of clomiphene and are entirely devoid of the estrogenically active (Z)-stereoisomer of clomiphene. In various examples, compositions are enclosed in a rapidly disintegrating capsule configured for immediate release. In preferred embodiments, the carrier comprises microcrystalline cellulose that functions as both bulk filler and disintegrant.

## Claims

### Claim 1

A pharmaceutical composition for treatment of testosterone deficiency (TD) and/or secondary hypogonadotropic hypogonadism, said composition comprising:
at least one selective estrogen receptor modulator (SERM);
a carrier; and
optionally, an excipient;
wherein the composition is in the form of a loose dry powder amenable to packaging into individual dosage forms, and
wherein the composition is entirely devoid of estrogenically active substances.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the selective estrogen receptor modulator (SERM) is selected from the group consisting of tamoxifen, toremifene, raloxifene, lasofoxifene, bazedoxifene, enclomifene, pharmaceutically acceptable salts thereof, and mixtures thereof.

### Claim 3 (depends on 1)

A pharmaceutical dosage form for oral administration comprising:
a capsule; and
a composition according to claim 1 enclosed therein.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the carrier comprises microcrystalline cellulose.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the optional excipient is at least one of a disintegrant, a colorant, a flavoring agent, a sweetener, a preservative, and a stabilizer.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1 consisting essentially of enclomifene ((E)-2-(4-(2-chloro-1,2-diphenylvinyl)phenoxy)-N,N-diethylethan-1-amine) and microcrystalline cellulose, wherein the pharmaceutical composition is entirely devoid of zuclomifene ((Z)-2-(4-(2-chloro-1,2-diphenylvinyl)phenoxy)-N,N-diethylethan-1-amine).

### Claim 7

A single dose pharmaceutical capsule consisting essentially of:
from about 100 mg to about 300 mg of a composition consisting essentially of from about 15 wt. % to about 25 wt. % enclomifene citrate and from about 75 wt. % to about 85 wt. % microcrystalline cellulose, based on the total weight of the composition; and
a capsule enclosing said composition,
wherein said composition is entirely devoid of zuclomifene ((Z)-2-(4-(2-chloro-1,2-diphenylvinyl)phenoxy)-N,N-diethylethan-1-amine), or salts, solvates, hydrates, or prodrugs thereof.

### Claim 8 (depends on 7)

The single dose pharmaceutical capsule of claim 7, wherein the capsule comprises gelatin or vegetarian hydroxypropyl methylcellulose (HPMC), and wherein the capsule is optionally laser-perforated with a plurality of holes for water ingress.

### Claim 9

A method of treating testosterone deficiency (TD) and/or secondary hypogonadotropic hypogonadism in a male individual, the method comprising orally administering to the individual in need thereof a therapeutically effective amount of a composition comprising at least one selective estrogen receptor modulator (SERM); a carrier; and optionally, an excipient, wherein the composition is entirely devoid of estrogenically active substances.

### Claim 10 (depends on 9)

The method of claim 9, wherein the testosterone deficiency (TD) and/or secondary hypogonadotropic hypogonadism is characterized by reduced sex drive, erectile dysfunction, loss of body hair, reduced beard growth, muscle atrophy, fatigue, or depression.

### Claim 11 (depends on 9)

The method of claim 9, wherein the testosterone deficiency (TD) and/or secondary hypogonadotropic hypogonadism is characterized by testicular atrophy caused by injectable testosterone replacement therapy (TRT).

### Claim 12 (depends on 9)

The method of claim 9, wherein the therapeutically effective amount comprises orally administering from about 3 mg to about 50 mg of the at least one SERM daily.

### Claim 13 (depends on 9)

The method of claim 9, wherein the at least one SERM is enclomifene ((E)-2-(4-(2-chloro-1,2-diphenylvinyl)phenoxy)-N,N-diethylethan-1-amine) and the carrier is microcrystalline cellulose.

### Claim 14 (depends on 13)

The method of claim 13, wherein the therapeutically effective amount comprises daily administration of a capsule enclosing said composition, wherein each capsule comprises from about 120 mg to about 150 mg of the composition, and wherein each capsule delivers from about 3 mg to about 50 mg enclomifene actives.

### Claim 15 (depends on 14)

The method of claim 14, wherein each capsule delivers about 3.125 mg, 6.25 mg, 12.5 mg, 25 mg or 50 mg enclomifene actives.
